Livdelzi
Total Payments
$2.8M
Transactions
3,044
Doctors
1,203
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.8M | 3,044 | 1,203 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 343 | 44.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 286 | 36.2% |
| Travel and Lodging | $201,758 | 561 | 7.3% |
| Food and Beverage | $172,394 | 1,778 | 6.2% |
| Consulting Fee | $147,630 | 34 | 5.3% |
| Space rental or facility fees (teaching hospital only) | $13,000 | 6 | 0.5% |
| Education | $417.24 | 36 | 0.0% |
Payments by Type
General
$1.5M
2,701 transactions
Research
$1.2M
343 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | Gilead Sciences, Inc. | $698,295 | 0 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | Gilead Sciences, Inc. | $511,878 | 0 |
| An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) | Gilead Sciences, Inc. | $6,603 | 0 |
| A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients with Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) | Gilead Sciences, Inc. | $6,200 | 0 |
| An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid | Gilead Sciences, Inc. | $2,728 | 0 |
Top Doctors Receiving Payments for Livdelzi
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Ann Arbor, MI | $1.2M | 349 |
| , M.D | Gastroenterology | Brooklyn, NY | $48,164 | 36 |
| , M.D | Transplant Hepatology | Salt Lake City, UT | $47,519 | 42 |
| , M.D | Gastroenterology | Detroit, MI | $43,029 | 28 |
| , MD | Hepatology | New York, NY | $36,793 | 34 |
| , MD | Gastroenterology | Saint Louis, MO | $35,230 | 29 |
| , M.D | Gastroenterology | Detroit, MI | $34,968 | 24 |
| , DO | Gastroenterology | Allentown, PA | $31,549 | 20 |
| , M.D | Hepatology | Fort Worth, TX | $31,517 | 25 |
| , MD | Internal Medicine | Houston, TX | $30,029 | 26 |
| , MD | Internal Medicine | Chandler, AZ | $27,654 | 19 |
| , M.D | Gastroenterology | La Jolla, CA | $27,533 | 34 |
| , MD | Gastroenterology | New York, NY | $27,524 | 37 |
| , MD | Gastroenterology | Chicago, IL | $27,261 | 21 |
| , M.D | Gastroenterology | Parker, CO | $26,393 | 27 |
| , MD | Hepatology | Dallas, TX | $25,876 | 20 |
| , M.D | Gastroenterology | Bradenton, FL | $25,761 | 16 |
| , MD | Gastroenterology | Seattle, WA | $25,572 | 18 |
| , DO | Hepatology | Milwaukee, WI | $24,522 | 21 |
| , M.D | Hepatology | Pasadena, CA | $23,390 | 26 |
| , M.D | Internal Medicine | Orlando, FL | $22,396 | 11 |
| , MD | Hepatology | Cherry Hill, NJ | $21,689 | 32 |
| , M.D | Hepatology | Baltimore, MD | $20,140 | 26 |
| , M.D | Gastroenterology | Norfolk, VA | $19,620 | 25 |
| , MD | Gastroenterology | Phoenix, AZ | $18,909 | 27 |
Ad
Manufacturing Companies
- Gilead Sciences, Inc. $2.8M
Product Information
- Type Drug
- Total Payments $2.8M
- Total Doctors 1,203
- Transactions 3,044
About Livdelzi
Livdelzi is a drug associated with $2.8M in payments to 1,203 healthcare providers, recorded across 3,044 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences, Inc..
Payment data is available from 2024 to 2024. In 2024, $2.8M was paid across 3,044 transactions to 1,203 doctors.
The most common payment nature for Livdelzi is "Unspecified" ($1.2M, 44.4% of total).
Livdelzi is associated with 5 research studies, including "An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)" ($698,295).